UK Medicine Regulator, MHRA, approved the Moderna's bivalent vaccine that triggered a strong immune response against both Omicron and the original virus that was detected in 2020 Britain has achieved another milestone in the global battle against Covid-19 as it became the first nation to approve a bivalent vaccine that targets both the original and Omicron variant of the virus.
The bivalent vaccine, made by Moderna, has gained approval from the UK medicine regulator- Medicines and Healthcare products Regulatory Agency(MHRA) as a booster dose for adults.
The MHRA gave its approval for the vaccine based on the clinical trial data that indicated a triggered 'strong immune response' by the vaccine against the Omicron variant(BA.1) as well as the original Covid-19 virus, reported Reuters.
The exploratory analysis of the clinical trials reveals that the shot was also effective in generating an immune response against the currently prevalent Omicron offshoots BA.4 and BA.5.